Biogen’s tau-directed Alzheimer's program drew new attention as mid-stage results showed slower decline on multiple measures, with the strongest signal appearing in the lowest dose arm. Across 18 months in the Celia trial, BIIB080 was reported to outperform placebo and Biogen highlighted a 26% slowing of decline on CDR-SB in the low-dose group. However, analysts and trial reporting also underscored what may complicate the narrative: Celia’s dose-response readout moved in the “wrong” direction relative to the protocol’s statistical plan, and several endpoints reached only nominal significance versus placebo. Biogen previously disclosed technical failure but said it would continue development based on cognitive benefits and tau reductions. Together, the readout keeps alive the question of whether tau pathology can deliver clinical advantage comparable to established amyloid approaches such as Leqembi and Kisunla, but it leaves regulators and experts waiting for confirmatory data on dose optimization and clinically meaningful outcomes.